Researchers at the KAHER Institute of Physiotherapy in India found that 4 weeks of oropharyngeal stimulation or proprioceptive neuromuscular facilitation (PNF) therapy improved cognition and sleep in patients with obstructive sleep apnea (OSA). These results were published in the Journal of Sleep Disorders and Therapy.
Patients (N = 30) with OSA were recruited for this clinical study. Patients were randomized to receive 20 minutes of oropharyngeal stimulation between 30 and 100 Hz or tongue PNF training for 4 weeks. Patients were assessed using the Epworth Sleepiness Scale (ESS), Pittsburgh Sleep Quality Index (PSQI), Mindful Awareness Scale (MAAS), Addenbrooke Cognitive Examination-III (ACE-III), Trail Making Tests A and B ( TMT) and the Digit Span test (DST). Blood glucose levels were also tested.
The participants were 66.67% men with a mean age of 49.53 ± 8.98 years and 48.93 ± 8.84 years and body mass indices of 27.20 ± 2.57 kg / m2 and 26.33 ± 2.74 kg / m2 for the oropharyngeal or PNF group. At baseline, the oropharyngeal and PNF cohorts had significantly different ACE-III scores (t, 2.1185; P = 0.0431).
In the oropharyngeal stimulation group, significant differences were found between before and after the test for ESS (mean difference 9.73; t 6.1918; P = 0.0001), PSQI (mean difference 11.93; t 6.5225; P. =) observed. 0001), MAAS (mean difference 10.2; t 2.4227; P = 0.0296), TMT-A (mean difference 0.86; t 5.2256; P = 0.0001), TMT-B (mean Difference 1.71; t, 6.9848; P = 0.0001), DST (mean difference 0.81; t 5.0286; P = 0.0002) and glycated hemoglobin (mean difference 1.55; t 4, 9219; P = 0.0002).
In the PNF group of the tongue, significant differences were found between before and after the test for ESS (mean difference 9.87; t 9.8262; P = 0.0001), PSQI (mean difference 11.87; t 5.5052; P =) observed. 0001), ACE-III (mean difference -12.93; t 3.0289; P = 0.0090), TMT-A (mean difference 0.96; t 5.4833; P = 0.0001), TMT- B (mean difference 2.04); t, 4.4448; P = 0.0006) and glycated hemoglobin (mean difference 2.02; t, 3.7308; P = 0.0022).
At the follow-up, the oropharyngeal cohort differed significantly from the PNF group for PSQI (t, -2.288; P = 0.0299), ACE-III (t, -2.9526; P = 0.0063), TMT- B (t, 1.921); P = 0.065) and DST (t, -1.9481; P = 0.0615).
This study was limited by sample size, lack of a control group, or combinatorial therapy.
These data suggest that patients with OSA can benefit from either oropharyngeal stimulation or tongue PNF therapies, which can improve blood sugar, sleep quality, awareness, and cognition.
Bhore V, Chitra J, Parikh J. Effect of oropharyngeal stimulation and tongue PNF on cognition, sleep quality, and Hba1c in patients with obstructive sleep apnea – A randomized clinical trial. J Sleep disorder Ther. 2020; 9 (6): 320. doi: 10.35248 / 2167-02184.108.40.2060
This article originally appeared on Psychiatry Advisor